![\"\"](\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2026\/02\/CROI-page-banner-300x58.png\")
<\/p>\n<\/p>\n
Simon Collins, HIV i-Base<\/strong><\/p>\n From 22\u201325 February 2026, CROI will be held in Denver, Colorado and also as a hybrid meeting for online delegates.<\/strong><\/p>\n Maintaining both options is essential given the increasing concerns many people have about travelling to the US and the costs involved in attending international meetings. It is also linked to the Trump administration’s policies to cancel funding for many international health programmes and its increasingly anti-science agenda.<\/p>\n These policy changes are so dramatic that the CROI Foundation now proactively states the importance of scientific research and investment in public health. This statement also condemns the censoring of science and the withdrawal of funding for research and for evidence-based prevention and treatment programmes.<\/p>\n Although approximately 3000 delegates are registered to attend in person, international community attendance is likely to now be lower than in recent years.<\/p>\n This is no reflection on the quality of the research that will be presented over the next week. CROI is still one of the most important meetings for researchers to showcase their work, and as with previous meetings, this year has an exciting and varied programme.<\/p>\n This includes the preliminary programme that has already been posted online: A link to the full programme will be added here once it becomes available.<\/p>\n Access to abstracts will initially be restricted to delegates until either the end of the conference or a month later, but should then be accessible here: Selected podcasts and review video resources: One of the practical changes this year is that daily press conferences are no longer being held. This is a progressive development that might be considered by other conference organisers, including IAS.<\/p>\n The 2026 conference includes 1028 abstracts (from >1700 submitted), including 70 late-breakers. Of these, 98 are oral presentations, 47 in poster discussions and 930 posters.<\/p>\n Early reports from CROI 2026 will be added daily to the list below.<\/p>\n GLP-1 studies of weight loss drugs included short-term impact in a real world setting, potential benefits on reducing smoking, cardiovascular risk, depression, and liver fibrosis with the oral abstract on the potential to perhaps reverse the gut damage that occurs in very early HIV infection and that persists despite effective ART. Still lots of gaps in data though.<\/p>\n A new once-daily pill can effectively simplify ART for many on complicated combinations. This is a tiny pill – smaller than Biktarvy – and let many people stop boosted PIs – or other complex combinations used by older people who have been on ART for more than 20 years.<\/p>\n This new study is the second randomised clinical trial to report no benefit against gonorrhoea for gay men given the 4CMenB vaccine. Many questions for why these results are so different to observational studies and generated a lot of discussions and questions.<\/p>\n This phase 3 study showed that a new oral drug called pritelivir can work in people who have drug resistance to other herpes treatments. Available now in an expanded access programme while being reviewed by the FDA.<\/p>\n Long-term results from this 8-year French PrEP study in predominantly gay men continued to show efficacy of 2:1:1 dosing and the flexibility to switch to daily dosing and back depending on your circumstances.<\/p>\n Analysis of the impact of last year’s US policies \u2013 and inspiring strategies for how to overcome them this year. The talk drew on the unique and dynamic history of ACT-UP to give us strength and hope for the future, when the current US administration will be replaced..<\/p>\n The study looking as dose selection for this very exciting option for once-monthly oral PrEP.<\/p>\n An interesting study by independent investigators looking at this now discontinued PrEP drug against HIV with drug resistance. Luckily, this is unlikely to affect the new replacement compound MK-8527.<\/p>\n
\nhttps:\/\/www.croiconference.org\/preliminary-agenda<\/a><\/p>\n
\nhttps:\/\/www.croiconference.org\/search-abstracts<\/a><\/p>\n
\nhttps:\/\/www.croiconference.org\/our-voices<\/a><\/p>\nNew CROI policies and opening talks<\/h2>\n
Links to early reports<\/h2>\n
\n
\n
\n
\n
\n
\n
\n
\n